Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 61, Issue 7, Pages 953-962Publisher
SPRINGER
DOI: 10.1007/s00262-012-1254-0
Keywords
T cell; Gene modification; Chimeric antigen receptor; Cancer; Immunotherapy
Categories
Funding
- Cancer Research UK
- EU FP6 programme ATTACK
- Kay Kendall Leukaemia Fund
- FP7 training Network ATTRACT
Ask authors/readers for more resources
The adoptive transfer of chimeric antigen receptor (CAR)-expressing T cells is a relatively new but promising approach in the field of cancer immunotherapy. This therapeutic strategy is based on the genetic reprogramming of T cells with an artificial immune receptor that redirects them against targets on malignant cells and enables their destruction by exerting T cell effector functions. There has been an explosion of interest in the use of CAR T cells as an immunotherapy for cancer. In the pre-clinical setting, there has been a considerable focus upon optimizing the structural and signaling potency of the CAR while advances in bio-processing technology now mean that the clinical testing of these gene-modified T cells has become a reality. This review will summarize the concept of CAR-based immunotherapy and recent clinical trial activity and will further discuss some of the likely future challenges facing CAR-modified T cell therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available